AI assistant
Sending…
SOLESENCE, INC. — Director's Dealing 2021
Nov 24, 2021
33563_dirs_2021-11-24_75ec7fde-eead-4375-b598-256a5e7fb82f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NANOPHASE TECHNOLOGIES Corp (NANX)
CIK: 0000883107
Period of Report: 2021-11-22
Reporting Person: Cureton Kevin (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-11-22 | Common Stock | M | 11668 | $0.415 | Acquired | 37318 | Direct |
| 2021-11-22 | Common Stock | S | 11668 | $3.9204 | Disposed | 25650 | Direct |
| 2021-11-24 | Common Stock | M | 12332 | $0.415 | Acquired | 37982 | Direct |
| 2021-11-24 | Common Stock | M | 12393 | $0.52 | Acquired | 50375 | Direct |
| 2021-11-24 | Common Stock | S | 24725 | $3.77 | Disposed | 25650 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-11-22 | Common Stock (right to purchase) | $0.415 | M | 11668 | Disposed | 2023-02-14 | Common Stock (11668) | Direct |
| 2021-11-24 | Common Stock (right to purchase) | $0.415 | M | 12332 | Disposed | 2023-02-14 | Common Stock (36332) | Direct |
| 2021-11-24 | Common Stock (right to purchase) | $0.52 | M | 12393 | Disposed | 2024-02-13 | Common Stock (75000) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Common Stock (right to purchase) | $0.44 | 2025-02-18 | Common Stock (50000) | 50000 | Direct |
| Common Stock (right to purchase) | $0.42 | 2026-02-23 | Common Stock (43500) | 43500 | Direct |
| Common Stock (right to purchase) | $0.68 | 2027-02-21 | Common Stock (50000) | 50000 | Direct |
| Common Stock (right to purchase) | $0.82 | 2028-05-23 | Common Stock (80000) | 80000 | Direct |
| Common Stock (right to purchase) | $0.51 | 2029-05-22 | Common Stock (16500) | 16500 | Direct |
| Common Stock (right to purchase) | $0.45 | 2027-06-18 | Common Stock (90000) | 90000 | Direct |
Footnotes
F1: This line item represents the 1st sale of 11,668 shares of a total grant of 48,000 shares, leaving a balance of 36,332 shares remaining relating to this grant.
F2: This line item represents the 2nd sale, of 12,332 shares of a total initial grant of 48,000 shares, leaving a balance of 24,000 shares remaining relating to this grant.
F3: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
More from SOLESENCE, INC.
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
May 12
Regulatory Filings
2026
Apr 29
Annual Report
2026
Apr 23
Annual Report
2026
Mar 31
Regulatory Filings
2026
Mar 31
Director's Dealing
2025
Dec 30
Director's Dealing
2025
Dec 11
Regulatory Filings
2025
Dec 2
Regulatory Filings
2025
Dec 1